参考文献/References:
[1] Yu L,Lv JC,Zhou XJ,et al.Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients[J].Hum Genet,2011,129(3):335-344.DOI:10.1007/s00439-010-0927-z.
[2] Bonner C,Kerr-Conte J,Gmyr V,et al.Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion[J].Nat Med,2015,21(5):512-517.DOI:10.1038/nm.3828.
[3] Cabrera O,Berman DM,Kenyon NS,et al.The unique cytoarchitecture of human pancreatic islets has implications for islet cell function[J].Proc Natl Acad Sci USA,2006,103(7):2334-2339.DOI:10.1073/pnas.0510790103.
[4] Al Jobori H,Daniele G,Adams J,et al.Empagliflozin treatment is associated with improved β-cell function in type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2018,103(4):1402-1407.DOI:10.1210/jc.2017-01838.
[5] Kanno A,Asahara SI,Kawamura M,et al.Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes[J].J Diabetes Investig,2019,10(3):577-590.DOI:10.1111/jdi.12945.
[6] Shirakawa J,Tajima K,Okuyama T,et al.Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor and IGF-1 receptor-independent pathway[J].Diabetologia,2020,63(3):577-587.DOI:10.1007/s00125-019-05071-w.
[7] Jin J,Jin L,Luo K,et al.Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury[J].Am J Transplant,2017,17(10):2601-2616.DOI:10.1111/ajt.14316.
[8] Wei R,Cui X,Feng J,et al.Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice[J].Metabolism,2020,111:154324.DOI:10.1016/j.metabol.2020.154324.
[9] Daems C,Welsch S,Boughaleb H,et al.Early treatment with empagliflozin and GABA improves β-cell mass and glucose tolerance in streptozotocin-treated mice[J].J Diabetes Res,2019,2019:2813489.DOI:10.1155/2019/2813489.
[10] Kimura T,Obata A,Shimoda M,et al.Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice:the earlier and longer,the better[J].Diabetes Obes Metab,2018,20(10):2442-2457.DOI:10.1111/dom.13400.
[11] Vergari E,Knudsen JG,Ramracheya R,et al.Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion[J].Nat Commun,2019,10(1):139.DOI:10.1038/s41467-018-08193-8.
[12] Lv Q,Le L,Xiang J,et al.Liver transcriptomic reveals novel pathways of empagliflozin associated with type 2 diabetic rats[J].Front Endocrinol(Lausanne),2020,11:111.DOI:10.3389/fendo.2020.00111.
[13] Osataphan S,Macchi C,Singhal G,et al.SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms[J].JCI Insight,2019,4(5):e123130.DOI:10.1172/jci.insight.123130.
[14] Villani LA,Smith BK,Marcinko K,et al.The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration[J].Mol Metab,2016,5(10):1048-1056.DOI:10.1016/j.molmet.2016.08.014.
[15] Nakano D,Kawaguchi T,Iwamoto H,et al.Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells:multi-omics analysis of metabolomics and absolute quantification proteomics(iMPAQT)[J].PLoS One,2020,15(4):e0232283.DOI:10.1371/journal.pone.0232283.
[16] Gastaldelli A,Repetto E,Guja C,et al.Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes[J].Diabetes Obes Metab,2020,22(3):393-403.DOI:10.1111/dom.13907.
[17] ElMahdy MK,Helal MG,Ebrahim TM.Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α,IL-1β,and IL-18 in rat liver[J].Int Immunopharmacol,2020,86:106730.DOI:10.1016/j.intimp.2020.106730.
[18] Goto Y,Otsuka Y,Ashida K,et al.Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use[J].Endocr Connect,2020,9(7):599-606.DOI:10.1530/EC-20-0082.
[19] Uthman L,Baartscheer A,Schumacher CA,et al.Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients[J].Front Physiol,2018,9:1575.DOI:10.3389/fphys.2018.01575.
[20] Uthman L,Homayr A,Juni RP,et al.Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells[J].Cell Physiol Biochem,2019,53(5):865-886.DOI:10.33594/000000178.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(04):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(04):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]